Will Acadia Pharmaceuticals (ACAD) stock recover?
What do analysts say about ACAD?
Average price target from 12 analysts: $33 over ~12 months (Buy consensus), i.e. +77 % from the current price. Most reliable firm on ACAD: Cowen & Co. (100% hit rate, 3 scored calls). A target is a 12-month view, not for tomorrow.
What happened after its past drops?
Over 2013-2026, Acadia Pharmaceuticals saw 6 drops of 30%+. Twelve months later it was -5 % on median (positive 33% of the time). It regained its pre-crash high in 50% of cases, in about 20 months. (monthly history 2013-2026 — transparency data, not a guarantee)
ACAD's biggest months
⚠️ Drop measured from the 12-month high; analyst targets on a ~12-month horizon; monthly history since 2013. Information, not investment advice. Past performance does not guarantee future results.
Frequently asked questions
Will Acadia Pharmaceuticals stock recover?
No one can guarantee it, and we won't. What we know: it's down 30 % from its high; analysts target $33 over 12 months (+77 % from the current price). Over 2013-2026, Acadia Pharmaceuticals saw 6 drops of 30%+. Twelve months later it was -5 % on median (positive 33% of the time). It regained its pre-crash high in 50% of cases, in about 20 months. Past performance does not guarantee future results.
Why has ACAD dropped so much?
We don't assert the cause of a drop — a headline can be a consequence or a coincidence. What we measure is what comes next: the analysts' target and the stock's historical behavior after this kind of drop.
Should I buy ACAD now that it's down?
A drop is not a buy signal by itself. Cross-check with the analysts' target, their real reliability on the stock (most solid: Cowen & Co., 100% hit rate), and the fundamentals. This is not personalized advice.